Michael joined Lhasa Limited in 2015 as part of the Mirabilis project, aiding the research and curation of knowledge relevant to understanding the potential for purging of mutagenic impurities from drug substance syntheses. In 2017, Michael took over leadership of the scientific development of Mirabilis, working closely with leading members of the purge calculation community to develop both Mirabilis and the broader purge concept. More recently, Michael has been involved with a number of projects focusing on the ongoing nitrosamine challenges facing the pharma industry. As part of this work Michael has been working with academic institutions and industry bodies, such as the IQ consortium and USP, to find collaborative approaches to both understanding and subsequently addressing nitrosamine issues related to drug quality.